[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628260":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":53,"collaborators":25,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":25,"eligibilityCriteria":60,"healthyVolunteers":57,"sex":61,"minAge":62,"maxAge":25,"enrollmentInfo":63,"targetDuration":25,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":74,"overallStatus":76,"whyStopped":25,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Fu Jen Catholic University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with OSAS receiving dexmedetomidine for sedation during DISE","ACTIVE_COMPARATOR","Patients with obsturctive sleep apne syndrome receiving dexmedetomidine for sedation during drug-induced sleep endoscopy",[13],"Drug: Dexmedetomidine",{"label":15,"type":16,"description":17,"interventionNames":18},"Patients with OSAS receiving remimazolam for sedation during DISE","EXPERIMENTAL","Patients with obsturctive sleep apne syndrome receiving remimazolam for sedation during drug-induced sleep endoscopy",[19],"Drug: Remimazolam",[21,26],{"type":22,"name":23,"description":17,"armGroupLabels":24,"otherNames":25},"DRUG","Remimazolam",[15],null,{"type":22,"name":27,"description":11,"armGroupLabels":28,"otherNames":25},"Dexmedetomidine",[9],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Chao Hsien Sung, MD","CONTACT","0905302091","joe411002@gmail.com",[36],{"facility":37,"status":25,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Fu Jen Catholic University Hosptial","New Taipei City","Taiwan (r.o.c.)","24352","Taiwan","TW",{"type":44,"coordinates":45},"Point",[46,47],121.45703,25.06199,{"lat":47,"lon":46},[50],{"name":51,"role":32,"phone":52,"phoneExt":25,"email":34},"Chao-Hsien Sung, MD","886905302091",{"type":54,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100628260","the-use-of-remimazolam-versus-dexmedetomidine-for-patients-receiving-drug-induced-sleep-endoscopy-100628260",false,"NCT07459322","The Use of Remimazolam Versus Dexmedetomidine for Patients Receiving Drug-Induced Sleep Endoscopy","Inclusion Criteria:\n\n* Patients age \\> 18 years old\n* American Society of Ansthesiologists functional class \\\u003C III\n* Schedule to receive DISE exam for evaluation of OSAS\n\nExclusion Criteria:\n\n* Patient refusal\n* Allergic to experimental medication\n* History of central nervous system diseases\n* History of psychiatric diseases\n* Pregnancy\n* Severe, uncontrolled systemic diseases","ALL","18 Years",{"count":64,"type":65},60,"ESTIMATED","INTERVENTIONAL",[68],"NA","This study seeks to compare the clinical efficacy and safety of the novel sedative Remimazolam with Dexmedetomidine in Drug-Induced Sleep Endoscopy (DISE), evaluating their performance in sedation depth stability, incidence of adverse events, and postoperative recovery time, thereby providing evidence-based guidance for sedative selection in OSA patients. Additionally, it aims to develop a model for predicting upper airway obstruction sites by analyzing Polysomnography (PSG) data with artificial intelligence, enhancing diagnostic accuracy and treatment decision-making efficiency for Obstructive Sleep Apnea (OSA) to optimize clinical management.",[71,72,73],"OSAS (Obstructive Sleep Apneas Syndrome)","DISE","Sedation",[75,72,73,23,27],"OSAS","NOT_YET_RECRUITING","2026-03-04",{"date":79,"type":80},"2026-03-09","ACTUAL",{"date":82,"type":65},"2026-04-15",{"date":84,"type":65},"2027-12-31",{"name":5,"class":6},1]